Vesigen Therapeutics


Vesigen Therapeutics is a biotechnology company that develops groundbreaking therapeutic products. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables the delivery of a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and gene-editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets.

Industries

biotechnology
therapeutics

Nr. of Employees

small (1-50)

Vesigen Therapeutics

Cambridge, Massachusetts, United States, North America


Products

ARRDC1 Mediated Microvesicles (ARMMs)

A delivery platform for gene editing, RNA, and protein-based therapeutics, utilizing engineered extracellular vesicles for targeted therapy.

Non-viral Delivery Platform

A technology enabling the delivery of novel medicines, including gene editors and therapeutic RNA molecules, without using viral vectors.

Gene Editing Complex Delivery

Efficient delivery of gene editing complexes to various cell types in vitro and in vivo, supporting the development of genetic medicines.

Therapeutic RNA Molecule Delivery

Functional delivery of therapeutic RNA molecules across multiple cell types, demonstrating the platform's versatility in RNA-based therapy.

Protein-based Therapeutics Delivery

Enables the delivery of protein-based therapeutics to targeted cells and tissues, expanding the potential for protein therapies.

Disease-focused Therapeutic Programs

Development of therapeutic programs targeting neurological diseases, ocular conditions, and immune modulation using ARMMs technology.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.